Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.
Erasca, Inc. develops precision oncology therapies for cancers driven by the RAS/MAPK pathway. News on ERAS commonly centers on its RAS-targeting pipeline, including ERAS-0015, an investigational oral pan-RAS molecular glue evaluated in RAS-mutant solid tumors, and ERAS-4001, an oral pan-KRAS inhibitor for KRAS-mutant solid tumors.
Company updates frequently cover Phase 1 clinical data, dose-escalation results, trial collaborations and supply agreements, intellectual-property protection, development rights, public offering activity, financial results, and healthcare conference presentations. Recurring cancer settings in company disclosures include non-small cell lung cancer, pancreatic adenocarcinoma, colorectal cancer, and other RAS-mutant solid tumors.
Erasca, Inc. (Nasdaq: ERAS) reported its financial results for Q2 2021, revealing a net loss of $28.2 million, or $(1.20) per share, compared to a loss of $5.5 million in Q2 2020. The company successfully closed a $345 million IPO, enhancing its cash position to $198.7 million. Erasca initiated its HERKULES-1 clinical trial for ERAS-007 and nominated ERAS-3490 as a development candidate, both pivotal for targeting RAS/MAPK pathway-driven cancers. The company expects its cash reserves to fund operations for at least the next 24 months.
Erasca, Inc. (Nasdaq: ERAS) announced the closing of its initial public offering on July 20, 2021, raising $345 million by selling 21,562,500 shares at $16.00 each. This includes the underwriters' full exercise of an option for 2,812,500 additional shares. J.P. Morgan, Morgan Stanley, BofA Securities, Evercore ISI, and Guggenheim Securities were the joint book-running managers. The registration statement for the offering became effective on July 15, 2021. Erasca focuses on therapies targeting RAS/MAPK pathway-driven cancers, positioning itself as a leader in precision oncology.
Erasca, Inc. (Nasdaq: ERAS) has priced its upsized initial public offering at $16.00 per share for 18,750,000 shares, aiming for gross proceeds of $300.0 million. The shares are set to trade on Nasdaq starting July 16, 2021, with the offering closing on July 20, 2021, contingent on customary conditions. Underwriters have the option to purchase an additional 2,812,500 shares within 30 days. Erasca, focused on therapies for RAS/MAPK pathway-driven cancers, aims to leverage the funds for further development of its pipeline.